William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
View Older Stories View More Recent Stories
-
Duluth Holdings Inc. Announces Launch of Initial Public Offering
-
William Blair Downgrades ZS Pharma (ZSPH) to Market Perform
-
William Blair Downgrades HomeAway (AWAY) to Market Perform
-
William Blair Downgrades Franklin Covey (FC) to Market Perform
-
William Blair Downgrades ARC Document Solutions (ARC) to Market Perform
-
Revance Therapeutics (RVNC) Prices 3.25M Common Offering at $36/Share
-
Revance Therapeutics Announces Pricing of Public Offering of Common Stock
-
Fitch Rates Waterbury, CT's Series 2015 GOs 'A+'; Outlook Stable
-
Charlesbank Capital Partners Makes Investment in Plaskolite, Inc.
-
William Blair Starts CPI Card Group (PMTS) at Outperform
-
Revance Therapeutics (RVNC) Announces 3.25M Stock Offering
-
Revance Therapeutics Announces Proposed Public Offering of Common Stock
-
William Blair Downgrades Thermon Group Holdings (THR) to Market Perform
-
William Blair Downgrades Silicon Labs (SLAB) to Market Perform
-
FTJ FundChoice Surpasses $5 Billion in Assets Under Administration, Achieves Record AUA Growth of 81.9% Over 3 Year Period
-
Apple defies China slowdown fears with strong iPhone sales
-
Pomeroy and Tolt Solutions to Combine to Create The Pomeroy Group of Companies, a Leading Provider of IT Infrastructure Solutions and Managed Services
-
William Blair Trims EnerSys (ENS) to Market Perform; Johnson Controls (JCI) Deal Seen as Inevitable
-
Platinum Equity to Sell Information Technology Solutions Provider Pomeroy
-
Pomeroy and Tolt Solutions to Combine to Create The Pomeroy Group of Companies, a Leading Provider of IT Infrastructure Solutions and Managed Services
-
Is the Long Awaited Telcom Spending Cycle Lifting Juniper (JNPR)?
-
Berkshire Partners to Acquire Affordable Care
-
Strong Channel Checks Show Cisco (CSCO) Taking Share in Security and Server Markets
-
Voce Capital Sends Letter to Board of Air Methods Corporation Reiterating Call for Urgent Action
-
William Blair Downgrades Waddell & Reed (WDR) to Market Perform
-
Notable Analyst Rating Changes 10/16: (LULU) (TWOU) (CBD) Upgraded; (ATHN) (AWR) (NAV) Downgraded
-
Honeywell revenue misses on weak demand from oil, gas customers
-
William Blair Downgrades Allstate (ALL) to Underperform
-
Patriot National (PN) Announces $80M Common Stock Follow-on Offering
-
Patriot National Announces Launch of Follow-on Offering
-
CPI Card Group Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
William Blair Downgrades Imprivata (IMPR) to Market Perform
-
Ulmart: Russian Investment Update - Identify Sector Leaders and Invest in Them Now
-
Oppenheimer & Co. Names Eric Helenek Managing Director & Head of Alternative Capital Finance
-
Aclaris Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Aclaris Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Notable Analyst Rating Changes 10/13: (TOL) (MPEL) (POT) Upgraded; (ACI) (SKYW) (PHM) Downgraded
-
William Blair Upgrades General Electric (GE) to Outperform
-
Form SC 13G/A NEUSTAR INC Filed by: BLAIR WILLIAM & CO/IL
-
Form SC 13G NEUSTAR INC Filed by: WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
-
Form SC 13G ENCORE CAPITAL GROUP Filed by: WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
-
Sarepta Therapeutics Announces Closing of $127 Million Public Offering of Common Stock
-
CPI Card Group (PMTS) IPO Opens Up 10%, Movers Higher
-
William Blair Starts Atara Biotherapeutics (ATRA) at Outperform
-
CPI Card Group (PMTS) Sees IPO Price at $10/Share
-
CPI Card Group Prices Initial Public Offering
-
Aclaris Therapeutics (ACRS) IPO Opens 9% Higher
-
PlacementTracker Publishes Third Quarter 2015 PIPE Market League Tables
-
Aclaris Therapeutics (ACRS) IPO Prices at $11, Well Below Expected Range
-
Aclaris Announces Pricing of Initial Public Offering

